Literature DB >> 13820498

Cantharidin treatment of digital and periungual warts.

J H EPSTEIN, W L EPSTEIN.   

Abstract

Seventy-six digital and periungual warts in 40 patients were treated topically with cantharidin, a potent blistering agent. The material, dissolved in equal parts of acetone and collodion, was applied directly to the warts. Occlusion facilitated blistering. No pretreatment was required. The warts were re-treated at weekly intervals until clinically cured.Fifty-six per cent of digital warts and 33 per cent of periungual warts cleared after a single application of cantharidin. Few required more than three treatments. Observation was continued for more than six months in more than half of the cases. Cure was lasting in about 70 per cent of the cases in which the long term result was known. Cantharidin ranks with liquid nitrogen in effectiveness, but it is painless to apply and does not cause scarring. For these reasons it is especially useful in children.The main disadvantage is pain and tenderness at the treated site for two to four days in some patients. This can be avoided by careful application of the drug. Occasionally new warts appear at the edge of the cantharidin blister. They are best treated by curettage and desiccation.

Entities:  

Keywords:  CANTHARIDES/therapy; PAPILLOMA/therapy

Mesh:

Substances:

Year:  1960        PMID: 13820498      PMCID: PMC1578244     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  3 in total

1.  The nature of cantharidin acantholysis.

Authors:  R B STOUGHTON; F BAGATELL
Journal:  J Invest Dermatol       Date:  1959-11       Impact factor: 8.551

2.  Wart relapses at the edges of therapeutic cantharidin blisters.

Authors:  G H FINDLAY
Journal:  Arch Dermatol       Date:  1959-11

3.  Treatment of warts with cantharidin.

Authors:  W L EPSTEIN; A M KLIGMAN
Journal:  AMA Arch Derm       Date:  1958-05
  3 in total
  3 in total

1.  Phase II, Double-Blind, Vehicle-Controlled Study to Determine the Cantharidin Dose Regimen, Efficacy, Safety, and Tolerability of VP-102 in Subjects with External Genital Warts.

Authors:  Scott Guenthner; Wendy McFalda; Melita Tate; Kimberly Eads; Jayson Rieger; David K Glover; Cynthia Willson; Pamela Rumney; Ted Rosen; Jennifer Andres; Melissa Olivadoti
Journal:  Am J Clin Dermatol       Date:  2021-09-13       Impact factor: 7.403

2.  Real-life treatment of cutaneous warts with cantharidin podophyllin salicylic acid solution.

Authors:  Anh Ly Nguyen; Koen D Quint; Jan Nico Bouwes Bavinck; Angelina Erceg; Wim J A de Kort; John E M Körver
Journal:  Dermatol Ther       Date:  2019-11-20       Impact factor: 2.851

3.  COVE-1: A Phase 2, Open-Label Study to Evaluate Efficacy and Safety and the Optimal Regimen of VP-102, a Proprietary Drug-Device Product Containing Topical Cantharidin (0.7% w/v) Under Occlusion for the Treatment of Common Warts.

Authors:  Scott Guenthner; Wendy McFalda; Pearl Kwong; Kimberly Eads; Morgan McCafferty; Jayson Rieger; David K Glover; Cynthia Willson; Patrick Burnett; Melissa Olivadoti
Journal:  Dermatol Ther (Heidelb)       Date:  2021-07-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.